Logo

Baxter's Homechoice Claria APD System Receives the US FDA's 510 (k) Clearance for Kidney Failure

Share this

Baxter's Homechoice Claria APD System Receives the US FDA's 510 (k) Clearance for Kidney Failure

Shots:

  • Baxter has received the FDA’s clearance for its APD system designed for home use- combining it with Sharesource that aims to help patients with kidney disease manage their care remotely
  • The Homechoice Claria system was cleared for both adults and children. Its interface is available in 38 languages and features step-by-step- voice-activated instructions through an app to guide the user through therapy
  • The clearance follows the recent finalization of the ESRD ETC payment model aims to increase the number of new patients with kidney failure who receive home dialysis and organ transplants. Homechoice Claria with Sharesource will be available in the US in the coming weeks

 ­ Ref: Baxter | Image: BusinessWire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions